share_log

BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5

BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5

BMO Capital維持對Macrogenics的市場表現評級,將其目標價降至5美元。
Benzinga ·  08/07 11:12  · 評級/大行評級

BMO Capital analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Market Perform and lowers the price target from $8 to $5.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論